CDK12: A Potent Target and Biomarker for Human Cancer Therapy

被引:41
|
作者
Liang, Shujing [1 ,2 ,3 ]
Hu, Lifang [1 ,2 ,3 ]
Wu, Zixiang [1 ,2 ,3 ]
Chen, Zhihao [1 ,2 ,3 ]
Liu, Shuyu [1 ,2 ,3 ]
Xu, Xia [1 ,2 ,3 ]
Qian, Airong [1 ,2 ,3 ]
机构
[1] Northwestern Polytech Univ, Lab Bone Metab, Xian Key Lab Special Med & Hlth Engn, Xian 710072, Peoples R China
[2] Northwestern Polytech Univ, Key Lab Space Biosci & Biotechnol, Res Ctr Special Med & Hlth Syst Engn, Xian 710072, Peoples R China
[3] Northwestern Polytech Univ, NPU UAB Joint Lab Bone Metab, Sch Life Sci, Xian 710072, Peoples R China
基金
中国国家自然科学基金;
关键词
cyclin-dependent kinase 12; gene transcription; cell cycle; cell proliferation; DNA damage response; cancer therapy; CYCLIN-DEPENDENT-KINASES; DNA-DAMAGE RESPONSE; PROLINE-RICH MOTIFS; PRE-MESSENGER-RNA; C-TERMINAL DOMAIN; SH3; DOMAIN; CELL-CYCLE; BREAST-CANCER; PROTEIN; TRANSCRIPTION;
D O I
10.3390/cells9061483
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cyclin-dependent kinases (CDKs) are a group of serine/threonine protein kinases and play crucial roles in various cellular processes by regulating cell cycle and gene transcription. Cyclin-dependent kinase 12 (CDK12) is an important transcription-associated CDK. It shows versatile roles in regulating gene transcription, RNA splicing, translation, DNA damage response (DDR), cell cycle progression and cell proliferation. Recently, increasing evidence demonstrates the important role ofCDK12in various human cancers, illustrating it as both a biomarker of cancer and a potential target for cancer therapy. Here, we summarize the current knowledge ofCDK12, and review the research advances ofCDK12 ' s biological functions, especially its role in human cancers and as a potential target and biomarker for cancer therapy.
引用
收藏
页码:1 / 15
页数:15
相关论文
共 50 条
  • [21] CDK12/13 inhibition in ovarian cancer cell lines
    Fiegl, H.
    Hovdar, L.
    Handle, F.
    Santer, F.
    Tsibulak, I
    Wieser, V
    Ausserlechner, M. J.
    Schnaiter, S.
    Zeimet, A. G.
    Marth, C.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (04) : 5 - 5
  • [22] Lack of evidence for CDK12 as an ovarian cancer predisposing gene
    Alexandre Eeckhoutte
    Mathilde Saint-Ghislain
    Manon Reverdy
    Virginie Raynal
    Sylvain Baulande
    Guillaume Bataillon
    Lisa Golmard
    Dominique Stoppa-Lyonnet
    Tatiana Popova
    Claude Houdayer
    Elodie Manié
    Marc-Henri Stern
    Familial Cancer, 2020, 19 : 203 - 209
  • [23] Effects of CDK12/13 Inhibition in Patients with Ovarian Cancer
    Hovdar, L.
    Roessler, J.
    Hechenberger, P.
    Rainer, S.
    Ausserlechner, K.
    Greiderer-Kleinlercher, B.
    Ausserlechner, M.
    Marth, C.
    Zeimet, A. G.
    Fiegl, H.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E25 - E25
  • [24] Analysis of CDK12 alterations in a pan-cancer database
    Pan, Elizabeth
    Cabal, Angelo
    Javier-DesLoges, Juan
    Patel, Devin
    Panian, Justine
    Lee, Suzanna
    Shaya, Justin
    Nonato, Taylor
    Xu, Xiaojun
    Stewart, Tyler
    Rose, Brent
    Shabaik, Ahmed
    Cohen, Ezra
    Kurzrock, Razelle
    Tamayo, Pablo
    McKay, Rana R.
    CANCER MEDICINE, 2022, 11 (03): : 753 - 763
  • [25] Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
    Dieter, Sebastian M.
    Siegl, Christine
    Codo, Paula L.
    Huerta, Mario
    Ostermann-Parucha, Anna L.
    Schulz, Erik
    Zowada, Martina K.
    Martin, Sylvia
    Laaber, Karin
    Nowrouzi, Ali
    Blatter, Mona
    Kreth, Sina
    Westermann, Frank
    Benner, Axel
    Uhrig, Ulrike
    Putzker, Kerstin
    Lewis, Joe
    Haegebarth, Andrea
    Mumberg, Dominik
    Holton, Simon J.
    Weiske, Joerg
    Toepper, Lena-Marit
    Scheib, Ulrike
    Siemeister, Gerhard
    Ball, Claudia R.
    Kuster, Bernhard
    Stoehr, Gabriele
    Hahne, Hannes
    Johannes, Sarah
    Lange, Martin
    Herbst, Friederike
    Glimm, Hanno
    CELL REPORTS, 2021, 36 (03):
  • [26] Paclitaxel Overload Supramolecular Oxidative Stress Nanoamplifier with a CDK12 Inhibitor for Enhanced Cancer Therapy
    Zhang, Hao
    Xing, Chengyuan
    Yan, Binyuan
    Lei, Hanqi
    Guan, Yupeng
    Zhang, Shiqiang
    Kang, Yang
    Pang, Jun
    BIOMACROMOLECULES, 2024, 25 (06) : 3685 - 3702
  • [27] A selective Cdk12/13 non-covalent inhibitor with potent anti-breast cancer activity
    Quereda, V.
    Bayle, S.
    Francesca, V.
    Andrii, M.
    William, R.
    Derek, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [28] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Hamman, Kristin
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    FASEB JOURNAL, 2017, 31
  • [29] Targeting the transcriptional kinases CDK12 and CDK13 in breast and ovarian cancer
    Bradley, Michael
    Marineau, Jason
    Choi, Yoon
    Hamman, Kristin
    Malojcic, Goran
    Orlando, David
    Ren, Yixuan
    Ke, Nan
    Hu, Shanhu
    Olson, Eric
    Fritz, Christian
    Roberts, Christopher
    CANCER RESEARCH, 2017, 77
  • [30] The emerging roles of CDK12 in tumorigenesis
    Paculova, Hana
    Kohoutek, Jiri
    CELL DIVISION, 2017, 12